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Estrogen receptorAbstract Objective: This study aimed at determination of the MRI predictors of triple negative
breast cancer (TNBC) in comparison to other breast cancer subtypes.
Materials and methods: The study retrospectively enrolled 185 female patients with 206 patholog-
ically conﬁrmed invasive breast cancers with different subtypes by immunohistochemistry. Histopa-
thological analysis as well as MRI features of TNBC was compared to those of other breast cancer
subtypes. MRI features included the tumor size, shape, margin, internal enhancement, intratumoral
signal intensity on T2-WI, detectability by DW-MRI and ADC values.
Results: TNBCs showed higher histological grades (p< 0.0001) and younger patient age group
(p= 0.006) compared to other tumor subtypes. At MRI, TNBCs were of larger size
(p< 0.0001), round shape (p< 0.0001), smooth margin (p< 0.0001), with rim enhancement
(p< 0.0001) and higher incidence of T2-WI tumoral hyperintensity (p= 0.0002) and intratumoral
necrosis (p< 0.0001). No signiﬁcant difference in tumor detectability was found by DW-MRI,
however, TNBCs had higher ADC values (p< 0.0001).
Conclusion: In our study, TNBC patients were of younger age with higher grade malignancy.
TNBC MRI predictors were unifocal rim enhancing mass with round shape, smooth margin, higher
signal intensity on T2-WI, in addition to relatively larger sizes of tumors associated with high inci-
dence of intratumoral necrosis and higher ADC values.
 2014 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier
B.V.Open access under CC BY-NC-ND license.1. Introduction
Triple negative breast cancer (TNBC) is deﬁned by lack of
expression of estrogen, progesterone and human epidermal
growth factor receptor 2 (HER2) receptors (1). TNBC
accounts for 11–20% of all subtypes of breast cancers (2,3),
but accounts for 23–28% of locally advanced disease and
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TNBC is characterized by distinct molecular, histopatholo-
gical, and clinical features including a particularly aggressive
clinical course and the lack of effective targeted therapies
and hence unfavorable prognosis (6,7). Although TNBC has
been extensively studied, there are few reports on the imaging
features of TNBC (8).
Multiple studies have reported that endocrine therapy is
not beneﬁcial in treatment of TNBC, thus chemotherapy is
currently the mainstay of systemic medical treatment. How-
ever, patients with TNBC have a worse outcome after chemo-
therapy than patients of other breast cancer subtypes (9).
Recently, analyses of gene expression proﬁles with cDNA
microarray technology have segregated breast cancers into sev-
eral subtypes with common molecular features: luminal A and
B (both estrogen receptor (ER)-positive), basal-like (BL) and
HER2-positive (all ER negative) (10–14). Approximately
70% of TN breast cancers are BL tumors. Currently, targeted
therapy for breast cancer is guided in large part by the status of
ER, PR and HER2, i.e., ER or PR for endocrine therapy and
HER2 for anti-HER2 therapy. By immunohistochemistry,
three major breast cancer subtypes are categorized: triple-
negative (i.e., ER-, PR- and HER2-negative), HER2-positive
(i.e., HER2-positive; ER and PR may be positive or negative),
and ER-positive (i.e. ER positive, HER2-negative, PR may be
positive or negative) types (15,16). These immunohistochemi-
cal subtypes correspond roughly to the molecular subtypes
of basal-like, HER2-positive and luminal, respectively (17).
More than 90% of BL breast cancers and TNBCs present
as invasive ductal carcinomas of no special type and are usu-
ally high-grade, demonstrate a high mitotic index, and contain
central necrotic regions, pushing borders of invasion, and
obvious lymphocytic inﬁltration (9,18).
TNBCs frequently present as palpable masses and may
carry benign features on mammography and ultrasound imag-
ing, which in turn may cause errors or delay in their accurate
diagnosis. Consequently, mammography may be of limited
value in screening patients who are at an increased risk of
developing TNBC (8). Moreover, assessment of the palpable
mass in core needle biopsy is less reliable than in excisional
biopsy owing to smaller sample size or heterogeneous tumor
status.
So, if it is possible to predict triple-negative breast cancer
on the basis of imaging features particularly MRI characteris-
tics, this additional information could assist in both pretreat-
ment planning and prognosis.
This study was performed to determine the MRI predictors
of triple negative invasive breast cancer (TNBC) on DCE-MRI
and on DW-MRI in comparison to other breast cancer sub-
types (ER-positive (ER+) and HER2-positive (HER2+)
cancers.2. Materials and methods
This study was conducted retrospectively in Ain Shams Uni-
versity Hospitals during the period from January 2012 to
November 2013. We reviewed during this period all histopath-
ologic and immunohistochemistry reports of patients whose
core or excisional biopsies, breast conserving surgery, or mas-
tectomy specimens were examined and proved to have invasive
breast cancer, breast cancer subtype of each case was retrieved.Of these patients, those who performed MRI breast before
biopsy taking or pre-operative at our Radiology Department,
their MRI examinations were recruited through the database
system and were reinterpreted for multiple MRI parameters
which were then correlated to the histopathologic report in
an attempt to detect possible MRI imaging predictors differen-
tiating TNBC from other breast cancer subtypes. Patients
enrolled in our study performed MRI breast examination for
variety of reasons including indeterminate mammographic
and sonographic ﬁndings, accurately detecting the extent of
disease, BIRADS (Breast Imaging Reporting and Data
System) 3 or 4 masses in sonomammography with clinical sus-
picion of malignancy.
2.1. Patients
After reviewing the histopathology results, we identiﬁed 453
invasive breast cancers. We included in our study 206 breast
cancers in 185 female patients aged 29 to 67 years (mean
48.2 years); 21 cases had bilateral breast cancer. Patients
underwent MRI breast study at our Radiology Department
before biopsy taking or pre-operative. We excluded the
remaining 247 breast cancers of total identiﬁed 453 cancers
for two reasons; 242 cancers in 242 patients did not have breast
MRI examinations, in addition to 5 cancers in 5 patients, who
had already started chemotherapy before the breast MRI
examination, their exams were discarded for fear of change
of tumor morphology. In patients with multifocal breast can-
cer, we selected the largest lesion in tumor analysis.
2.2. Breast MRI
All MRI examinations were performed with an Achieva;
Philips Medical Systems, Bothell, WA, USA. All patients were
examined in the prone position using a breast array coil. MRI
protocol applied in our study was as follows: A survey
sequence was followed by axial T1 and T2WI fast spin-echo
sequence, axial and sagittal STIR fat suppressed images, single
shot echo-planar DW imaging were obtained for both breasts
prior to contrast administration, tri-directional diffusion gra-
dients were used with b values: 0, 400 and 800 s/mm2 to
increase sensitivity to cellular packing, respiratory triggering
was used for better resolution. Number of excitations was 2;
matrix used was 256 · 256; and ﬁeld of view of 34 cm; slice
thickness was 3 mm and gap was 0. Dynamic contrast
enhanced (DCE) sequence with axial and sagittal post-contrast
T1WI fat suppressed images were taken after bolus injection of
0.1 mmol gadopentate dimeglumine per kilogram of body
weight. The injection rate was 2 mL/s, followed by 20 mL sal-
ine ﬂush. One acquisition was performed prior to contrast
administration and three acquisitions were performed over a
period of 6 min after intravenous contrast material injection.
At EasyVision; Philips Medical Systems workstation, ADC
values were measured and time signal intensity curves were
generated. The ADC values for the different b-values were
obtained by placing 4 regions of interest (ROIs) on the ADC
map in the area with pathological enhancement. The (ROI)
area was between 1 and 2 cm2, the ﬁnal ADC value was the
average of the 4 measured values for each b-value. Time inten-
sity curves were generated by drawing region of interest (ROI)
at the area of maximum higher visual enhancement, care was
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egorized into three types (persistent (continuous), plateau, or
washout pattern).
2.3. Interpretation of MR imaging ﬁndings
Blinded to histopathologic and immunohistochemistry results,
the consultant radiologist with women’s imaging subspecialty
reviewed each breast MRI examination for the targeted breast
lesion using the Breast Imaging Reporting and Data System
(BIRADS) MR lexicon (19) with respect to: its location, mor-
phology, visual evaluation of signal intensity in fat suppressed
T2WI. Signal intensity on fat suppressed T2WI was deter-
mined as lower than, equivalent to, or higher than that of
the surrounding breast tissue, its signal in DWI and corre-
sponding ADC value and enhancement pattern with analysis
of time/signal intensity curves.3. Histopathology and immunohistochemistry
3.1. Technique
Pathologic reports from core needle, excisional biopsies, breast
conserving surgery or mastectomy specimens were reviewed to
identify invasive breast cancers with determination of the fol-
lowing prognostic factors: histologic grade and tumor subtype.
Histologic grading was performed by the Elston–Ellis method
(20), in which tubule formation, pleomorphism, and mitotic
counts are scored 1–3 points. Cases scored within 3–5 ranged
as grade 1, within 6–7 as grade 2, and within 8–9 as grade 3,
in addition, necrosis within the tumor was recorded. Tissue
sections which were Formalin-ﬁxed and parafﬁn-embedded tis-
sue were immunohistochemically stained with appropriate
antibodies for ER (Dako, Carpinteria, CA, USA), PR (Dako,
Carpinteria, CA, USA) and HER2 (Dako, CA, USA). Avidin
Biotin immunoperoxidase complex technique was used by
applying the super sensitive detection kit (Biogenex, CA,
USA). The prepared tissue sections were ﬁxed on poly-L-lysine
coated slides overnight at 37 C. They were deparafﬁnized in
xylene, and rehydrated in graded alcohol series. Endogenous
peroxidase activity was inhibited by immersing the sections
in 3% methanol hydrogen peroxide for 10 min. Antigen retrie-
val was performed in a 20-mmol/L concentration of citrate
buffer (pH 6.0) for 10 min. The sections were incubated for
2 h at room temperature, with the primary antibody. Biotinyl-
ated antimouse immunoglobulin and streptavidin conjugated
to horseradish peroxidase were then added. Finally, 3,3-diam-
inobenzidine as the substrate or chromogen was used to form
an insoluble brown product. The slides were counterstained
with hematoxylin (DAKO) and coverslipped using a non aque-
ous mounting medium.
3.2. Interpretation
The status of each receptor was considered to be negative if the
expression was less than 10% and positive if the expression
was 10% or greater. The HER2 expression was semiquantita-
tively assessed as follows: 0 for no membranous staining, 1+
for weak uneven membranous staining in some of the tumor
cells, 2+ for weak to moderate membranous staining in a largenumber of tumor cells, and 3+ for strong and complete mem-
branous staining in almost all of the tumor cells.
4. Statistical analysis
To compare the MR imaging ﬁndings between TNBC, ER+
and HER2+ breast cancers, we used x2 for categorical
variables and ANOVA test for comparison of mean values
or single variable. All analyses were performed by using
software (SPSS, version 11.0; SPSS, Chicago, Ill), p< 0.05 is
considered to indicate a signiﬁcant difference.
5. Results
This study included 206 invasive breast cancers in 185 female
patients, 42/206 (20.4%) were TNBC, 98/206 (47.6%) were
ER+ and 66/206 (32.0%) were HER2+. Younger patients’
age was detected in TNBC (mean value = 43.1 ± 8.2,
p= 0.006) compared to ER+ (45 ± 6.1) and HER2+
(47.4 ± 6.6) (Table 1). All breast cancer histological types
were as follows: invasive ductal carcinoma (IDC) (n= 186),
invasive lobular carcinoma (ILC) (n= 6), mucinous carci-
noma (n= 6), medullary carcinoma (n= 6) and metaplastic
carcinoma (n= 2) (Table 1). Regarding the results comparing
pathological variables among the three tumor subtypes
(Table 1), tumor histological grade was signiﬁcantly different
among tumor subtypes (p< 0.0001). The percentage of histo-
logical grade 3 (Fig. 1f) in TNBC (26/42, 61.9%) was higher
than that of ER+ (17/98, 17.3%) or HER2+ (21/66,
31.8%). Regarding MRI features (Table 2); all tumors were
detected as areas of abnormal enhancement. The majority of
lesions in all tumor subtypes showed mass like enhancement
(36/42, 85.7% vs. 90/98, 91.8% and 63/66, 95.6% for TNBC,
ER+ and HER2+, respectively) (p= 0.199). On DCE-
MRI, larger tumor size was found in TNBC subtype
(p< 0.0001) (25.4 ± 4.1 mm in TNBC vs. 19.8 ± 3.8 mm
and 24.7 ± 5.2 mm in ER+ and HER2+, respectively). Most
of tumors in the three subtypes were unifocal lesions
(p= 0.256). The majority of TNBC subtype with mass like
enhancement had round shape (24/42, 66.7%) (p< 0.0001)
(Fig. 1), while 75/98, 83.3% and 52/66, 82.5% of ER+ and
HER2+ subtypes had irregular shapes (Figs. 2 and 3). The
margins of TNBCs were most frequently smooth (26/42,
72.2%) (p< 0.0001) (Fig. 1), while in ER+ and HER2+
margins were mostly spiculated (Fig. 3) in 60/98, 66.6% and
46/66, 73.0%, respectively. Intratumoral necrosis was found
in 32/42, 76.2% of TNBCs (Fig. 1) versus 29/98, 29.6% and
15/66, 22.7% in ER+ and HER2+ subtypes. The predomi-
nant internal enhancement pattern of the TNBCs was rim
enhancement (Fig. 1) identiﬁed in 22/42, 61.1%
(p< 0.0001), while heterogenous internal enhancement was
the predominant in ER+ (Fig. 2) and HER2+ (Fig. 3) sub-
types, 65/98, 74.5% and 54/66, 85.7%, respectively. No statis-
tically signiﬁcant difference was found regarding the
distribution and internal enhancement of non mass like can-
cers among the three tumor subtypes (p= 0.554 and 0.425,
respectively). Intratumoral high signal intensity with respect
to the surrounding breast tissue on unenhanced fat suppressed
T2-weighted images was identiﬁed in 30/42, 71.4% of TNBCs
(Fig. 1) which corresponded morphologically and pathologi-
cally to intratumoral necrosis, compared to 38/98, 38.8%
Table 1 Histopathologic data of patients with TN, ER+ and HER2+ breast cancer subtypes.
Histopathological features Tumor subtype
TN (42 tumors) ER+ (98 tumors) HER2+ (66 tumors) p value
Patients’ age (mean) 43.1 ± 8.2 45 ± 6.1 47.4 ± 6.6 0.006
Histological grade <0.0001
1 (low) 4 (9.5%) 52 (53.1%) 10 (15.1%)
2 (moderate) 12 (28.6%) 29 (25.6%) 35 (53.0%)
3 (high) 26 (61.9%) 17 (17.3%) 21 (31.8%)
Histological type 0.0733
IDC (NOS) 36 (85.7%) 92 (93.9%) 58 (87.9%)
ILC 1 (2.4%) 4 (4.1%) 1 (1.5%)
Medullary 2 (4.8%) 0 4 (6.1%)
Metaplastic 0 0 2 (3.0%)
Mucinous 3 (7.1%) 2 (2.0%) 1 (1.5%)
Abbreviations: TN= triple negative; ER = estrogen receptor; HER2 = human epidermal growth factor receptor; IDC = invasive ductal
carcinoma; NOS = not otherwise speciﬁed; ILC = invasive lobular carcinoma.
Figure 1 TNBC IDC of the left breast in 33-year old-female. (a)
Axial contrast enhanced T1-WI with fat suppression showing left
breast 31.5 mm round mass with smooth margin and rim
enhancement pattern (arrow). (b) Time signal intensity curve
shows initial rise then persistent (continuous) pattern. (c) Axial fat
suppressed T2-WI indicates very high central signal intensity
corresponding to intratumoral necrosis (arrow). (d and e) DWI
and ADC map respectively showing peripheral restricted diffusion
and low ADC (arrowed) (mean ADC value was
1.102 · 103 ± 0.111). (f) H and E stain showing grade 3 IDC
with solid inﬁltrating masses of malignant cells. (g) Negative ER
immunostaining.
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(p= 0.0002). Time intensity analysis revealed type III (wash-
out) and type II (plateau) curves in 26/42, 61.9% of TNBC
compared to 92/98, 93.8% and 64/66, 97.0% in ER+ and
HER2+, respectively (p< 0.0001) (Figs. 2 and 3), while 16/
42, 38.1% of TNBCs showed type I persistent (continuous)
curve (Fig. 1). Visual delectability of the three tumor subtypes
at DWI was not signiﬁcantly different among tumor subtypes.
ADC values were signiﬁcantly different among tumor subtypes
(p< 0.0001), the mean ADC value of TNBC was
1.097 · 103 mm2/s which was higher than that of ER+
(0.620 · 103 mm2/s) or HER2+ (0.632 · 103 mm2/s).
6. Discussion
TNBC has been studied extensively in the oncology and
pathology literature; however, few reports are available
describing its imaging features. Current literature suggests that
imaging features of TNBC are signiﬁcantly different from
other primary breast cancer immunotypes (8).
Similar to previous reports (9,18,21–26), our study results
showed that TNBCs were associated with younger patients’
age (mean; 43.1 years, p= 0.006), high tumor grades (26/42,
61.9% grade 3, p< 0.0001) but no statistically signiﬁcant dif-
ference was found between the histologic types of TNBC and
the other subtypes. IDC (NOS) was the predominant histolog-
ical type (36/42, 85.7%, p= 0.073).
In the current literature, DCE-MRI most signiﬁcant fea-
tures associated with TNBCs were: round or oval shape
(22,24,27), smooth mass margin (22–25,27), rim type of inter-
nal enhancement (22–24,27–29), high signal intensity on fat
suppressed T2-weighted images (T2-WI) (22,23,25,30) and
higher ADC values (22,31–33). Other contradictory features
were: unifocal lesion (23–25,30), larger size of tumor mass
(21,22,25,26,30) and malignant type time signal intensity
curves (wash out or plateau) (22–25,27,30). In our study,
TNBCs showed many features in DCE-MRI which were in
concordance with the previously mentioned results, which
were unifocality of tumors (37/42, 88.1%, p= 0.2567), round
shape (24/42, 66.7%, p< 0.0001), smooth mass margin (26/
42, 72.2%, p< 0.0001), TNBCs had the largest tumor size
(25.4 ± 4.1, p< 0.0001), rim enhancement (22/42, 61.1%,
p< 0.0001) and higher ADC values (mean 1.097 ± 203.9,
Table 2 MRI features of TN, ER+ and HER2+ breast cancer subtypes.
Tumor subtype p value
TN (42 tumors) ER+ (98 tumors) HER2+ (66 tumors)
MRI parameters
T2-WI signal intensity 0.0002
Low/equal 12 (28.6%) 60 (61.2%) 44 (66.6%)
High/very high 30 (71.4%) 38 (38.8%) 22 (33.4%)
DCE-MRI
Tumor size (mm) 25.4 ± 4.1 19.8 ± 3.8 24.7 ± 5.2 <0.0001
Multifocality 0.2567
Yes 5 (11.9%) 14 (14.3%) 4 (6.1%)
No 37 (88.1%) 84 (85.7%) 62 (93.9%)
Presence of intratumoral necrosis <0.0001
Yes 32 (76.2%) 29 (29.6%) 15 (22.7%)
No 10 (23.8%) 69 (70.4%) 51 (77.3%)
Morphology 0.199
Mass 36 (85.7%) 90 (91.8%) 63 (95.6%)
Non mass 6 (14.3%) 8 (8.2%) 3 (4.5%)
Mass
Shape <0.0001
Round 24 (66.7%) 10 (11.1%) 6 (9.5%)
Oval 3 (8.3%) 5 (5.6%) 2 (3.2%)
Lobular 1 (2.8%) 0 3 (4.8%)
Irregular 8 (22.2%) 75 (83.3%) 52 (82.5%)
Margin <0.0001
Smooth 26 (72.2%) 0 0
Irregular 7 (19.4%) 30 (33.3%) 15 (27.0%)
Spiculated 3 (8.4%) 60 (66.7%) 46 (73.0%)
Internal enhancement <0.0001
Homogenous 5 (13.9%) 18 (20.0%) 6 (9.5%)
Heterogenous 9 (25.0%) 65 (74.5%) 54 (85.7%)
Rim 22 (61.1%) 7 (7.1%) 3 (4.8%)
Non mass
Distribution 0.554
Focal 0 0 0
Linear 0 1 (12.5%) 0
Ductal 0 0 1 (33.3%)
Segmental 4 (66.7%) 3 (37.5%) 1 (33.3%)
Regional 2 (33.3%) 4 (50.0%) 1 (33.3%)
Internal enhancement 0.425
Homogenous 3 (50.0%) 4 (50.0%) 1 (33.3%)
Heterogenous 2 (33.3%) 1 (37.5%) 2 (66.7%)
Clumped 1 (16.7%) 3 (12.5%) 0
Kinetic curves <0.0001
I (persistent) 16 (38.1%) 6 (6.1%) 2 (3.0%)
II (plateau) 7 (16.7%) 7 (7.1%) 4 (6.1%)
III (wash out) 19 (45.2%) 85 (86.7%) 60 (90.9%)
DW-MRI
ADC (mean value · 103 mm2/s) 1.097 · 103 ± 0.203 0.620 · 103 ± 0.148 0.632 · 103 ± 0.162 <0.0001
Abbreviations: TN= triple negative; ER = estrogen receptor; HER2 = human epidermal growth factor receptor; DCE= dynamic contrast
enhanced magnetic resonance imaging; DW= diffusion weighted; ADC= apparent diffusion coefﬁcient.
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Most of breast cancer subtypes including TNBCs in this study
showed malignant pattern kinetic curves (type II and III),
however a signiﬁcant difference was found between the 3
tumor subtypes (p< 0.0001) as 16/42, 38.1% of TNBCs
showed persistent (type I) kinetic curves, this may beattributed to non homogenous tumor enhancement which
was also declared by Uematsu et al. (23) who found that
TNBCs in their study had predominant persistent (continuous)
pattern curves (p= 0.005) (23).
Putti et al. (34) resulted in their study that TNBCs were
characterized morphologically by high grade, smooth margin
Figure 2 Recurrent ER+ IDC of the right breast in a 53-year-
old female after conservative breast surgery (lumpectomy). (a)
MIP shows multifocal pattern of recurrence (arrow). (b) Axial
contrast enhanced T1-WI with fat suppression showing the largest
mass measuring 21.5 · 23.1 mm, irregular in shape with irregular
margin and heterogenous enhancement (arrow). (c) Time intensity
curve indicates rapid initial rise then wash out pattern. (d) Axial
fat suppressed T2-WI showing high signal of the mass (arrow). (e
and f) DWI and ADC map respectively showing restricted
diffusion and low ADC (arrowed) (mean ADC value was
0.823 · 103 ± 0.106). (g) H and E stain showing grade 2 IDC
with sheets and tubules of malignant cells. (g) Strong nuclear
positivity for ER immunostaining.
Figure 3 HER2+ IDC of the right breast in a 41-year-old
female. (a and b) Axial and sagittal contrast enhanced T1-WI with
fat suppression showing an irregular 34.3 · 20.4 mm spiculated
mass (arrow). (b) Time intensity curve shows initial rise followed
by plateau pattern. (c) Axial T2-WI with fat suppression showing
isointense signal of the mass (arrow) to the surrounding breast
tissue. (d and e) DWI and ADC map respectively showing
restricted diffusion and low ADC (arrowed) (mean ADC value
was 0.734 · 103 ± 0.109). (g) H and E showing grade 1 IDC with
angulated tubules and cellular stroma. (h) Positive HER2 immu-
nostaining (2+) with moderate complete membranous staining in
large number of the tumor cells.
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in which MRI revealed intratumoral necrosis in 32/42, 76.2%
(p< 0.0001) (Table 2) of TNBC groups compared to 29/98,
29.6% and 15/66, 22.7% in ER+ and HER2+ subtypes
respectively. All intratumoral necrosis were proven by histopa-
thological analysis.
In this study, 90 of 206 breast cancers showed signal hyper-
intensity on fat suppressed T2-weighted images, 30 tumors
were TNBC representing 71.4% of TNBC group
(p= 0.0002) (Table 2). Twenty seven of 30 TNBCs with high
signal in fat suppressed T2-weighted images had intratumoral
central necrosis while 3 tumors were hyperintense withoutnecrosis; their histopathology analysis revealed that they were
mucinous carcinomas. We could correlate the hyperintensity in
fat suppressed T2-WI in our study to the central necrosis in
most of the cases. This result could be supported by the ﬁnding
that in all 27 cases, areas of tumor necrosis showed no
Triple negative breast cancer 1315restriction at DW-MRI and ADC map with corresponding
high ADC values. These results were concordant with Uema-
tsu et al. (23) and Metz et al. (35), who resulted in their studies
that intratumoral necrosis correlated to hyperintensity on T2-
WI (p< 0.001) and was signiﬁcantly associated with TNBCs
(23). In addition, Youk et al. (22) and Uematsu et al. (23)
found that areas of tumor necrosis showed a signiﬁcant corre-
lation with increased diffusion and higher ADC values on
DWI and was found more frequently in cases of TNBC.
Another explanation for increased ADC value in TNBCs
was reported by Ludovini et al. and kim et al. (32,36) who sta-
ted that in ER+ tumors, the ADC value becomes less than in
ER–as the estrogen receptors inhibit the tumor angiogenesis
decreasing perfusion and thus affecting the ADC value.
In our study, rim internal enhancement was predominant in
TNBCs (22/42, 61.1%, p< 0.0001) (Table 2), this may be due
to tumor necrosis compared to predominant heterogenous
internal enhancement in the other subtypes. Our results are
consistent with many studies (22–24,27–29). Teifke et al. (30)
declared that rim enhancement is the most useful MR feature
for identifying TNBC. Rim enhancement is associated with
higher grade tumors (37,38) and tends to predict an unfavor-
able prognosis for malignant lesions especially those with
smooth margins (36). It is observed that rim enhancing masses
with a smooth margin are typical features of masses associated
with triple-negative breast cancer (23).
No statistical signiﬁcance was found between breast cancer
tumor subtypes as regards the mass type lesion where all tumor
subtypes were predominantly of mass type (p= 0.199)
(Table 2), this was concordant with many reports
(21,24,25,27,30), the distribution and internal enhancement
patterns of the non mass type of tumors (p= 0.554 and
p= 0.425, respectively) (Table 2), similar results were found
by Youk et al. (22) and Choi et al. (31) as well as regarding
the visual detectability of tumors at DW-MRI, similar results
were found by Youk et al. (22).
In conclusion, our study resulted that TNBC patients were
of younger age with higher grade malignancy. TNBC pre-
sented several MRI predictors on DCE-MRI such as unifocal
rim enhancing mass with round shape, smooth margin, higher
signal intensity on fat suppressed T2-WI, in addition to rela-
tively larger size of tumors associated with high incidence of
intratumoral necrosis and higher ADC values on DWI. These
features could be beneﬁcial in identifying TNBC from ER+
and HER2+ breast cancer subtypes.
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